Literature DB >> 34094589

Engineered materials for in vivo delivery of genome-editing machinery.

Sheng Tong1, Buhle Moyo1, Ciaran M Lee1, Kam Leong2, Gang Bao1.   

Abstract

Genome editing technologies, such as CRISPR/Cas9, are promising for treating otherwise incurable genetic diseases. Great progress has been made for ex vivo genome editing; however, major bottlenecks exist in the development of efficient, safe, and targetable in vivo delivery systems, which are needed for the treatment of many diseases. To achieve high efficacy and safety in therapeutic in vivo genome editing, editing activities must be controlled spatially and temporally in the body, which requires novel materials, delivery strategies, and control mechanisms. Thus, there is currently a tremendous opportunity for the biomaterials research community to develop in vivo delivery systems that overcome the problems of low editing efficiency, off-targeting effect, safety, and cell and tissue specificity. In this Review, we summarize delivery approaches and provide perspectives on the challenges and possible solutions, aiming to stimulate further development of engineered materials for in vivo delivery of genome-editing machinery.

Entities:  

Year:  2019        PMID: 34094589      PMCID: PMC8174554          DOI: 10.1038/s41578-019-0145-9

Source DB:  PubMed          Journal:  Nat Rev Mater        ISSN: 2058-8437            Impact factor:   66.308


  117 in total

1.  Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells.

Authors:  Marianela Candolfi; James F Curtin; Wei-Dong Xiong; Kurt M Kroeger; Chunyan Liu; Altan Rentsendorj; Hasmik Agadjanian; Lali Medina-Kauwe; Donna Palmer; Philip Ng; Pedro R Lowenstein; Maria G Castro
Journal:  Mol Ther       Date:  2006-06-23       Impact factor: 11.454

2.  Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN.

Authors:  Christian Hinderer; Nathan Katz; Elizabeth L Buza; Cecilia Dyer; Tamara Goode; Peter Bell; Laura K Richman; James M Wilson
Journal:  Hum Gene Ther       Date:  2018-02-12       Impact factor: 5.695

Review 3.  Physical Principles of Nanoparticle Cellular Endocytosis.

Authors:  Sulin Zhang; Huajian Gao; Gang Bao
Journal:  ACS Nano       Date:  2015-08-21       Impact factor: 15.881

4.  Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing.

Authors:  Qiurong Ding; Alanna Strong; Kevin M Patel; Sze-Ling Ng; Bridget S Gosis; Stephanie N Regan; Chad A Cowan; Daniel J Rader; Kiran Musunuru
Journal:  Circ Res       Date:  2014-06-10       Impact factor: 17.367

5.  CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells.

Authors:  Daniel P Dever; Rasmus O Bak; Andreas Reinisch; Joab Camarena; Gabriel Washington; Carmencita E Nicolas; Mara Pavel-Dinu; Nivi Saxena; Alec B Wilkens; Sruthi Mantri; Nobuko Uchida; Ayal Hendel; Anupama Narla; Ravindra Majeti; Kenneth I Weinberg; Matthew H Porteus
Journal:  Nature       Date:  2016-11-07       Impact factor: 49.962

6.  Rapid and tunable method to temporally control gene editing based on conditional Cas9 stabilization.

Authors:  Serif Senturk; Nitin H Shirole; Dawid G Nowak; Vincenzo Corbo; Debjani Pal; Alexander Vaughan; David A Tuveson; Lloyd C Trotman; Justin B Kinney; Raffaella Sordella
Journal:  Nat Commun       Date:  2017-02-22       Impact factor: 14.919

7.  Insertional Mutagenesis by CRISPR/Cas9 Ribonucleoprotein Gene Editing in Cells Targeted for Point Mutation Repair Directed by Short Single-Stranded DNA Oligonucleotides.

Authors:  Natalia Rivera-Torres; Kelly Banas; Pawel Bialk; Kevin M Bloh; Eric B Kmiec
Journal:  PLoS One       Date:  2017-01-04       Impact factor: 3.240

8.  Therapeutic Genome Editing With CRISPR/Cas9 in a Humanized Mouse Model Ameliorates α1-antitrypsin Deficiency Phenotype.

Authors:  Mikael Bjursell; Michelle J Porritt; Elke Ericson; Amir Taheri-Ghahfarokhi; Maryam Clausen; Lisa Magnusson; Therese Admyre; Roberto Nitsch; Lorenz Mayr; Leif Aasehaug; Frank Seeliger; Marcello Maresca; Mohammad Bohlooly-Y; John Wiseman
Journal:  EBioMedicine       Date:  2018-02-19       Impact factor: 8.143

9.  A Self-Deleting AAV-CRISPR System for In Vivo Genome Editing.

Authors:  Ang Li; Ciaran M Lee; Ayrea E Hurley; Kelsey E Jarrett; Marco De Giorgi; Weiqi Lu; Karol S Balderrama; Alexandria M Doerfler; Harshavardhan Deshmukh; Anirban Ray; Gang Bao; William R Lagor
Journal:  Mol Ther Methods Clin Dev       Date:  2018-12-06       Impact factor: 6.698

10.  Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy.

Authors:  Christopher E Nelson; Yaoying Wu; Matthew P Gemberling; Matthew L Oliver; Matthew A Waller; Joel D Bohning; Jacqueline N Robinson-Hamm; Karen Bulaklak; Ruth M Castellanos Rivera; Joel H Collier; Aravind Asokan; Charles A Gersbach
Journal:  Nat Med       Date:  2019-02-18       Impact factor: 53.440

View more
  20 in total

1.  Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection.

Authors:  Zhifen Cui; Cong Zeng; Furong Huang; Fuwen Yuan; Jingyue Yan; Yue Zhao; Yufan Zhou; William Hankey; Victor X Jin; Jiaoti Huang; Herman F Staats; Jeffrey I Everitt; Gregory D Sempowski; Hongyan Wang; Yizhou Dong; Shan-Lu Liu; Qianben Wang
Journal:  Nat Chem Biol       Date:  2022-07-25       Impact factor: 16.174

2.  Controlling the Biological Fate of Liposomal Spherical Nucleic Acids Using Tunable Polyethylene Glycol Shells.

Authors:  Wuliang Zhang; Cassandra E Callmann; Chad A Mirkin
Journal:  ACS Appl Mater Interfaces       Date:  2021-09-21       Impact factor: 10.383

Review 3.  CRISPR Modeling and Correction of Cardiovascular Disease.

Authors:  Ning Liu; Eric N Olson
Journal:  Circ Res       Date:  2022-06-09       Impact factor: 23.213

4.  A Versatile Nonviral Delivery System for Multiplex Gene-Editing in the Liver.

Authors:  Jing Gong; Hong-Xia Wang; Yeh-Hsing Lao; Hanze Hu; Naazanene Vatan; Jonathan Guo; Tzu-Chieh Ho; Dantong Huang; Mingqiang Li; Dan Shao; Kam W Leong
Journal:  Adv Mater       Date:  2020-10-14       Impact factor: 30.849

Review 5.  Therapeutic Genome Editing and In Vivo Delivery.

Authors:  Amanda Catalina Ramirez-Phillips; Dexi Liu
Journal:  AAPS J       Date:  2021-06-02       Impact factor: 4.009

Review 6.  Tools for experimental and computational analyses of off-target editing by programmable nucleases.

Authors:  X Robert Bao; Yidan Pan; Ciaran M Lee; Timothy H Davis; Gang Bao
Journal:  Nat Protoc       Date:  2020-12-07       Impact factor: 13.491

Review 7.  External stimuli-responsive nanoparticles for spatially and temporally controlled delivery of CRISPR-Cas genome editors.

Authors:  Ruosen Xie; Yuyuan Wang; Shaoqin Gong
Journal:  Biomater Sci       Date:  2021-09-14       Impact factor: 7.590

Review 8.  DNA Repair Pathway Choices in CRISPR-Cas9-Mediated Genome Editing.

Authors:  Chaoyou Xue; Eric C Greene
Journal:  Trends Genet       Date:  2021-04-22       Impact factor: 11.821

Review 9.  Spatiotemporal control of CRISPR/Cas9 gene editing.

Authors:  Chenya Zhuo; Jiabin Zhang; Jung-Hwan Lee; Ju Jiao; Du Cheng; Li Liu; Hae-Won Kim; Yu Tao; Mingqiang Li
Journal:  Signal Transduct Target Ther       Date:  2021-06-20

Review 10.  Harnessing lipid nanoparticles for efficient CRISPR delivery.

Authors:  Jingyue Yan; Diana D Kang; Yizhou Dong
Journal:  Biomater Sci       Date:  2021-09-14       Impact factor: 7.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.